Communicators

BioChem Solutions plans facility for arthritis, HIV drugs

Frankfurt, Germany -- Biochem Solutions Inc. today announced the start of negotiations with regulatory authorities in India to open a major manufacturing facility there for its Arthromir and Alphamir products, promising medicines in development for treatment of rheumatoid arthritis, HIV/AIDS and other acute infections.

Chennai, India, was selected following a year-long, global evaluation of seven competing locations. "In the final analysis, India's combination of business-friendly laws and economic-development incentives proved critical to our decision," said James C. Shelley, president of BioChem Solutions. "The clincher was India's ideal location near our real-world medical marketplace, countries throughout Africa and across the European Union.

"Millions upon many millions of patients in Africa and Europe will be the immediate and direct beneficiaries of our health-enhancing products," Shelley added. "India is the perfect platform from which to launch our production of these vital medicines.

James A. Herman, a BioChem Solutions director, will be in Chennai next month to finalize regulatory approvals and commence conversion of an existing manufacturing facility. Initial production of BioChem Solutions product at the renovated plant is slated for February 2009.

BioChem Solutions holds the worldwide master license to produce and distribute all products that incorporate the patented product Trioxolane as an active ingredient. Its first products are the trademarked derivatives Arthromir and Alphamir. Preliminary studies strongly suggest that Arthromir has significant potential in the clinical management of rheumatoid arthritis, while Alphamir shows similar promise in the treatment of HIV/AIDS patients.

Opening of the manufacturing facility fulfills a condition of a previously announced joint-venture agreement between Tropical II Ventures Ltd., BioChem Solutions' exclusive manufacturing and distribution agent in India, and Health India Laboratories Ltd., one of India's most respected health and wellness corporations. Tropical II Ventures is obligated to open the initial BioChem Solutions production facility within the first year of the agreement, during which Health India Laboratories is to obtain all regulatory approvals for commercial sales of BioChem Solutions products.

BioChem Solutions also holds the global master license to produce and market medications derived from the patented product Diperoxide. In trials to date, both Trioxolane and Diperoxide derivatives have shown significant improvement in the function of the human immune system using a variety of indicators.

The use of these derivatives has potential in destroying tumor cells and harmful micro-organisms such as bacteria, viruses, parasites and fungi. Treatment is non-toxic and has shown no adverse side effects. Moreover, these products reinforce natural immune systems in combating harmful agents and regulating the beneficial production of serotonin, prostaglandin and inflammatory interleukins.

Progress in the renovation and opening of the manufacturing facility will be posted at the new BioChem Solutions website, www.biochemsolutionsinc.com.

Company Contact: www.biochemsolutiosinc.com -- info@biochemsolutionsinc.com
U.S. Telephone: (305) 423-7108 Fax: (305) 908-7601

Stockinformation: WKN: A0J36E ISIN: US0909651046

Investor Relations:
Connecting Markets GmbH,
Große Bockenheimer Straße 50, 60313 Frankfurt, Germany
Tel. + 49 (0) 69 21 65 59 10
FAX + 49 (0) 69 21 65 59 11
email: info@cmir.de

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.


NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=US0909651046

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.